TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›OABI›Financials
Annual statements · SEC XBRL · FY2021 – FY2025

OmniAb, Inc. (OABI) financials

Income statement

OmniAb, Inc. (OABI) income statement, annual, from SEC filings
Fiscal yearFY2021FY2022FY2023FY2024FY2025
Revenue$34.7M$59.1M$34.2M$26.4M$18.7M
Revenue growth—70.0%-42.2%-22.8%-29.3%
Operating income-$35.6M-$26.6M-$69.4M-$74.5M-$69.0M
Operating margin-102.5%-45.1%-203.2%-282.3%-369.5%
Net income-$27.0M-$22.3M-$50.6M-$62.0M-$64.8M
Net margin-77.8%-37.8%-148.2%-235.1%-347.0%
EPS (diluted)-$0.33-$0.26-$0.51-$0.61-$0.57

Cash flow

OmniAb, Inc. (OABI) cash flow, annual, from SEC filings
Fiscal yearFY2021FY2022FY2023FY2024FY2025
Operating cash flow-$5.67M-$3.59M$2.35M-$39.7M-$36.5M
Capital expenditures$4.07M$17.2M$1.64M$1.88M$565K
Free cash flow-$9.74M-$20.8M$703K-$41.5M-$37.0M

Balance sheet

OmniAb, Inc. (OABI) balance sheet, annual, from SEC filings
Fiscal yearFY2021FY2022FY2023FY2024FY2025
Cash & equivalents$0.00$98.1M$16.4M$27.6M$25.5M
Total assets$304M$393M$375M$326M$301M
Total liabilities$70.2M$67.1M$60.6M$37.9M$33.9M
Shareholders' equity$234M$341M$315M$288M$267M
Retained earnings$0.00$11.3M-$39.4M-$101M-$166M
Shares (wtd avg diluted)82.6M82.6M99.7M102M114M

Every figure is extracted from OmniAb, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is OmniAb, Inc.'s annual revenue?
OmniAb, Inc. (OABI) reported $18.7M of revenue for fiscal year 2025 — down 29.3% from $26.4M in FY2024, per its annual report filed with the SEC.
Is OmniAb, Inc. profitable?
Not in FY2025 — OABI reported a net loss of $64.8M, per SEC filings.
What is OmniAb, Inc.'s free cash flow?
-$37.0M in FY2025 (operating cash flow -$36.5M minus $565K of capital expenditures), from the SEC cash-flow statement.
Does OABI pay a dividend?
OmniAb, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full OABI analysis — verdict, score & filings →Is OABI a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.